Outcome after percutaneous cholecystostomy for acute cholecystitis: a single-center experience
Background Percutaneous cholecystostomy is an alternative treatment for acute cholecystitis
patients with high surgical risk. Methods One hundred and sixty-six patients consecutively …
patients with high surgical risk. Methods One hundred and sixty-six patients consecutively …
Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression
YC Hsieh, SK Joo, BK Koo, HC Lin, DH Lee… - Clinical …, 2023 - Elsevier
Background & Aims Sarcopenia and myosteatosis are associated with advanced
nonalcoholic fatty liver disease (NAFLD). However, muscle alterations in early stage NAFLD …
nonalcoholic fatty liver disease (NAFLD). However, muscle alterations in early stage NAFLD …
Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease
YC Hsieh, SK Joo, BK Koo, HC Lin, W Kim - Liver International, 2021 - Wiley Online Library
Abstract Background & Aim Anthropometric data are associated with nonalcoholic fatty liver
disease (NAFLD) development and progression. We investigated whether the quantity and …
disease (NAFLD) development and progression. We investigated whether the quantity and …
[HTML][HTML] Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score
YC Hsieh, KC Lee, YW Wang, YY Yang, MC Hou… - PLoS …, 2018 - journals.plos.org
Background The role of noninvasive liver fibrosis markers which were developed to evaluate
the severity of chronic liver disease remains unclear in cirrhosis. Aims To evaluate the …
the severity of chronic liver disease remains unclear in cirrhosis. Aims To evaluate the …
[HTML][HTML] Microsatellite instability, Epstein–Barr virus, and programmed cell death ligand 1 as predictive markers for immunotherapy in gastric cancer
Simple Summary Immunotherapy is approved in selected cases of gastric cancer, and
durable responses have been observed in exceptional responders. Several potential …
durable responses have been observed in exceptional responders. Several potential …
[HTML][HTML] Eritoran attenuates hepatic inflammation and fibrosis in mice with chronic liver injury
Toll-like receptor 4 (TLR4) signaling plays a key role in liver inflammation and fibrosis. The
therapeutic effects of eritoran, a TLR4 antagonist, in mice with chronic liver injury remained …
therapeutic effects of eritoran, a TLR4 antagonist, in mice with chronic liver injury remained …
Poly (vinyl alcohol)/melamine composite containing LATP nanocrystals as a high-performing nanofibrous membrane separator for high-power, high-voltage lithium …
C Karuppiah, YC Hsieh, SL Beshahwured… - ACS Applied Energy …, 2020 - ACS Publications
Electrolyte uptake and thermal stability of separators are important factors in Li-ion battery
application. Here, a poly (vinyl alcohol)/melamine composite nanofiber membrane …
application. Here, a poly (vinyl alcohol)/melamine composite nanofiber membrane …
[HTML][HTML] (Pro) renin receptor knockdown attenuates liver fibrosis through inactivation of ERK/TGF-β1/SMAD3 pathway
YC Hsieh, KC Lee, HJ Lei, KH Lan, TI Huo… - Cellular and Molecular …, 2021 - Elsevier
Background & Aims Activation of the (pro) renin receptor (PRR) up-regulates the expression
of profibrotic genes in the kidney and heart. We aimed to investigate the role of PRR in …
of profibrotic genes in the kidney and heart. We aimed to investigate the role of PRR in …
[HTML][HTML] Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease
KC Lee, YC Hsieh, CC Chan, HJ Sun, YH Huang… - Laboratory …, 2019 - Elsevier
Human relaxin-2 reduces hepatic fibrosis in mice. However, the effects of relaxin-2 on
hepatic steatosis and fibrosis in animals with non-alcoholic fatty liver disease (NAFLD) …
hepatic steatosis and fibrosis in animals with non-alcoholic fatty liver disease (NAFLD) …
Dabigatran reduces liver fibrosis in thioacetamide-injured rats
KC Lee, WF Hsu, YC Hsieh, CC Chan, YY Yang… - Digestive Diseases and …, 2019 - Springer
Background Liver fibrosis can progress to cirrhosis, hepatocellular carcinoma, or liver
failure. Unfortunately, the antifibrotic agents are limited. Thrombin activates hepatic stellate …
failure. Unfortunately, the antifibrotic agents are limited. Thrombin activates hepatic stellate …